pISSN 2636-0004eISSN 2636-0012
pISSN 2636-0004Summary of Representative Published Data on EUS-RFA for Pancreatic Neoplasms
| Study | No. of patients | Indication ( |
RF device | Mean tumor size (range) | Application power and time | Mean RF sessions (range) | Technical success (%) | Clinical outcome ( |
Adverse events ( |
|---|---|---|---|---|---|---|---|---|---|
| Pai et al44 (2015) | 6 | Mucinous cyst (4), IPMN (1), microcystic adenoma (1), neuroendocrine tumor (2) | Habib EUS-RFA catheter | PCL: 36.5 (24–70), NET: 27.5 (15–40) | 5–25 W, 90–120 sec | 1.3 (1–2) | 100 | 2 cyst resolution, 4 cyst reduction, 50% reduction in 2 NETs with vascular changes | Mild abdominal pain (2) |
| Song et al2 (2016) | 6 | Locally advanced pancreatic cancer (4), metastatic pancreatic cancer (2) | EUSRA | 38 (30–90) | 20–50 W, 10 sec | 1.3 (1–2) | 100 | Necrosis at the ablation site | Mild abdominal pain (2) |
| Lakhtakia and Seo39 (2017) | 3 | Insulinoma | EUSRA | 19 (14–22) | 50 W, 10–15 sec | 1 | 100 | Complete resolution of hypoglycemia | None |
| Scopelliti et al48 (2018) | 10 | Locally advanced pancreatic cancer | EUSRA | 49.2 (35–75) | 20 or 30 W, 100–560 sec | 1.4 (1–2) | 100 | Necrosis at the ablation site | Mild abdominal pain (2), ascites (2), peripancreatic effusion (2) |
| Choi et al43 (2018) | 10 | NET (10), solid pseudopapillary neoplasm (2), insulinoma (1) | EUSRA | 20 (8–28) | 50 W | 1.6 (1–3) | 100 | Radiologic complete response (7) | Mild abdominal pain (1), acute pancreatitis (1) |
| Barthet et al42 (2019) | 29 | IPMN (16), MCN (1), NET (14 lesions in 12) | EUSRA | PCL: 28 (9–60), NET: 13.1 (10–20) | 50 W | NA | 100 | NET: radiologic complete response (12), PCL: complete response (11), > 50% reduction (1) | Acute pancreatitis (1), jejunal perforation (1), main pancreatic duct obstruction (1) |
EUS, endoscopic ultrasound; RFA, radiofrequency ablation; RF, radiofrequency; PCL, pancreatic cystic lesion; IPMN, intraductal papillary neoplasm; NET, neuroendocrine tumor; NA, not available.